Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

European stocks inch higher as AstraZeneca gains on UK vaccine approval

Published 12/30/2020, 04:22 PM
Updated 12/30/2020, 04:30 PM
© Reuters.

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
Dec 30 (Reuters) - European stocks edged higher on Wednesday
as Britain approved a COVID-19 vaccine developed by AstraZeneca
and Oxford University, while bets of more U.S. fiscal aid and
massive vaccination efforts spurred hopes of a strong global
economic recovery next year.
The pan-European STOXX 600 .STOXX rose 0.1% by 0810 GMT,
hovering near a 10-month high hit in the previous session.
Shares in AstraZeneca AZN.L were up 1.3% after jumping
3.3% earlier in anticipation of the news. The drugmaker said the
authorisation was for a two-dose regime, and that the vaccine
had been approved for use for emergency supply as Britain
battles a new, highly contagious variant of the virus.
Most markets in the region were subdued due to thin volumes
in a holiday-shortened week. The German DAX .GDAXI was flat,
while French .FCHI and Spanish stocks .IBEX slipped 0.1%
each.
Unicaja UNI.MC rose more than 2% and Liberbank LBK.MC
was down 3.6% after they announced an all-in share deal that
would create Spain's fifth-biggest bank with around 110 billion
euros ($134.71 billion) in assets.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.